TRML TOURMALINE BIO INC

Tourmaline Bio to Present at Upcoming Investor Conferences

Tourmaline Bio to Present at Upcoming Investor Conferences

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, will participate in the following investor conferences in March.

Jefferies Biotech on the Bay Summit, Miami

One-on-one and Small Group Meetings

March 12, 2024

Leerink Global Biopharma Conference, Miami

Corporate Presentation

March 13, 2024 at 10:00am ET

Live webcasts and replays, if available, will be posted under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at

About Tourmaline Bio, Inc. 

Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is TOUR006.

About TOUR006

TOUR006 is a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. To date, TOUR006 has been studied in 448 participants, including patients with autoimmune disorders, across six clinical trials. Tourmaline is developing TOUR006 in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD) as its first two indications, with additional diseases under consideration.

Contact:

Meru Advisors

Lee M. Stern



EN
27/02/2024

Underlying

TRMLTOURMALINE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TOURMALINE BIO INC

Laura Chico
  • Laura Chico
TRML TOURMALINE BIO INC
10/31/25 October 31, 2025 1 EN
Wedbush Research
  • Wedbush Research
LEN LENNAR CORPORATION CLASS A
AAPL APPLE INC.
IDYA IDEAYA BIOSCIENCES
TRML TOURMALINE BIO INC
CBIO CRESCENT BIOPHARMA INC.
09/09/25 September 9, 2025 1 EN
Laura Chico
  • Laura Chico
TRML TOURMALINE BIO INC
09/09/25 September 9, 2025 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG

Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG – Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion – – Transaction reflects the potential of Tourmaline’s pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential, for the treatment of cardiovascular diseases – – Transaction is expected to be completed in the fourth quarter of 2025, subject to customary closing conditions – NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”)...

September 9, 2025 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Tria...

Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress – Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across clinically-meaningful subgroups – – Pacibekitug demonstrated concordant, statistically significant reductions in secondary pharmacodynamic biomarkers of IL-6 pathway activity including lipoprotein(a), fibrinogen, and serum amyloid A – NEW YORK, Aug. 31, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage c...

August 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch